Exonate limited

Exonate Limited: Revolutionizing the Treatment of Age-Related Macular Degeneration

Exonate Limited is a biopharmaceutical company that is dedicated to developing innovative treatments for age-related macular degeneration (AMD). The company's primary focus is on wet AMD, which is a leading cause of blindness in people over the age of 50. Exonate's approach to treating wet AMD involves targeting VEGF alternative splicing, which has the potential to revolutionize the way this condition is treated.

What Is Age-Related Macular Degeneration?

Age-related macular degeneration (AMD) is a progressive eye disease that affects millions of people worldwide. It occurs when the macula, which is responsible for central vision, deteriorates over time. There are two types of AMD: dry and wet. Dry AMD accounts for about 90% of all cases and progresses slowly over time. Wet AMD, on the other hand, accounts for about 10% of cases but progresses much more rapidly and can lead to severe vision loss if left untreated.

The current standard treatment for wet AMD involves injecting anti-VEGF drugs directly into the eye every few weeks or months. While these drugs can be effective at slowing down or even stopping the progression of wet AMD, they are expensive and require frequent injections that can be uncomfortable and inconvenient for patients.

Exonate's Approach to Treating Wet AMD

Exonate Limited believes that there may be a better way to treat wet AMD by targeting VEGF alternative splicing. VEGF (vascular endothelial growth factor) plays an important role in angiogenesis (the formation of new blood vessels), which is necessary for normal tissue growth and repair. However, in conditions like wet AMD, abnormal blood vessel growth can occur in the retina, leading to vision loss.

By targeting VEGF alternative splicing with its proprietary technology platform called "ESG," Exonate aims to develop a new class of drugs that can selectively inhibit the abnormal blood vessel growth associated with wet AMD while leaving normal angiogenesis intact. This approach has the potential to be more effective and less invasive than current treatments for wet AMD.

Exonate's Pipeline

Exonate Limited has a robust pipeline of drug candidates in various stages of development. The company's lead candidate, EXN407, is a small molecule inhibitor that targets VEGF alternative splicing. In preclinical studies, EXN407 has shown promising results in reducing abnormal blood vessel growth in the retina without affecting normal angiogenesis.

In addition to EXN407, Exonate is also developing other drug candidates that target VEGF alternative splicing using its ESG platform. These include:

- EXN408: A second-generation small molecule inhibitor with improved potency and selectivity compared to EXN407.

- EXN409: A peptide-based inhibitor that targets VEGF alternative splicing.

- EXN410: An antisense oligonucleotide (ASO) inhibitor that targets VEGF alternative splicing.

All of these drug candidates have shown promising results in preclinical studies and are expected to enter clinical trials soon.

Exonate's Partnerships

Exonate Limited has formed several strategic partnerships with leading pharmaceutical companies and research institutions to advance its drug development programs. These partnerships include:

- Janssen Pharmaceuticals: In 2019, Exonate entered into a collaboration agreement with Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) to develop new treatments for retinal diseases using Exonate's ESG platform.

- University College London (UCL): Exonate has an ongoing collaboration with UCL's Institute of Ophthalmology to advance its understanding of VEGF alternative splicing and its role in retinal diseases.

- Medicines Discovery Catapult: In 2020, Exonate was awarded a grant from the Medicines Discovery Catapult to support the development of its drug candidates for wet AMD.

Conclusion

Exonate Limited is a biopharmaceutical company that is dedicated to developing innovative treatments for age-related macular degeneration (AMD), with a primary focus on wet AMD. The company's approach involves targeting VEGF alternative splicing, which has the potential to be more effective and less invasive than current treatments for wet AMD. With a robust pipeline of drug candidates and strategic partnerships with leading pharmaceutical companies and research institutions, Exonate is well-positioned to revolutionize the treatment of this debilitating condition.